Shelver W L, Keyler D E, Lin G, Murtaugh M P, Flickinger M C, Ross C A, Pentel P R
Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55415, USA.
Biochem Pharmacol. 1996 Feb 23;51(4):531-7. doi: 10.1016/0006-2952(95)02233-3.
Tricyclic antidepressant overdose can be reversed in rats by drug-specific antibody Fab fragments, but the required Fab dose may itself by toxic. We studied the potential use of a smaller, recombinant desipramine (DMI)-specific single chain Fv fragment (B9-sFv) for this purpose. Anesthetized rats received a tracer (subtoxic) dose of [3H]-DMI followed in 15 min by B9-IgG, B9-Fab, B9-sFv (0.1 mumol of binding sites) or BSA. Each of the active treatments produced a rapid and substantial increase in the serum radiolabel concentration, whereas BSA did not (P < 0.001). The increase in serum radiolabel concentration 1 min after treatment was 13.3-fold with B9-IgG, 10.0-fold with B9-Fab and 7.3-fold with B9-sFv. Serum antibody concentrations were also highest after B9-IgG and lower with B9-Fab or B9-sFv. The 24-hr urinary excretion of radiolabel did not differ among groups, but was extensive even in the BSA group and probably represented the excretion of DMI metabolites. B9-sFv concentrations in urine or buffer at 37 degrees declined by >90% over 24 hr, but this fragment was much more stable in serum, retaining 70% of its activity after 96 hr. These data demonstrate that B9-sFv can alter markedly the distribution of [3H]-DMI in vivo. The rapidity of this effect, and its magnitude in comparison with Fab fragment or IgG, suggest that further study of B9-sFv as a treatment of DMI overdose is warranted.
三环类抗抑郁药过量在大鼠中可通过药物特异性抗体Fab片段逆转,但所需的Fab剂量本身可能有毒。我们研究了为此目的使用更小的、重组的去甲丙咪嗪(DMI)特异性单链Fv片段(B9-sFv)的可能性。给麻醉的大鼠注射示踪剂(亚毒性)剂量的[3H]-DMI,15分钟后给予B9-IgG、B9-Fab、B9-sFv(0.1μmol结合位点)或牛血清白蛋白(BSA)。每种活性处理均使血清放射性标记物浓度迅速且大幅增加,而BSA则无此作用(P<0.001)。处理后1分钟血清放射性标记物浓度的增加倍数,B9-IgG为13.3倍,B9-Fab为10.0倍,B9-sFv为7.3倍。血清抗体浓度在B9-IgG后也最高,B9-Fab或B9-sFv较低。各实验组24小时放射性标记物的尿排泄量无差异,但即使在BSA组中也很高,可能代表DMI代谢产物的排泄。37℃时尿液或缓冲液中的B9-sFv浓度在24小时内下降>90%,但该片段在血清中更稳定,96小时后仍保留70%的活性。这些数据表明B9-sFv可显著改变[3H]-DMI在体内的分布。这种效应的快速性及其与Fab片段或IgG相比的程度,表明有必要进一步研究B9-sFv作为治疗DMI过量的药物。